Adendra Therapeutics develop treatments for cancers and autoimmune diseases by applying new insights into regulation of adaptive immune responses by dendritic cells
Adendra Therapeutics has raised €47M across 1 funding round from 1 investor, most recently a Series A round in Dec 2021. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-12-12 | Series A |
| €47M |
| ATP |
| View deal → |
